Skip to main content
Top
Published in: Digestive Diseases and Sciences 5/2014

01-05-2014 | UNM Clinical Case Conferences

A Case of Jaundice of Obscure Origin

Authors: Fahad M. Khan, Joseph Alcorn, Joshua Hanson

Published in: Digestive Diseases and Sciences | Issue 5/2014

Login to get access

Abstract

Background

Idiopathic painless jaundice with significant elevations in serum transaminases, occurring in a previously healthy patient, invokes a circumscribed set of possibilities including viral hepatitis, auto-immune hepatitis (AIH) and drug-induced liver injury (DILI).

Methods

In this described case, common causes of cholestatic jaundice were considered including drug-induced liver injury, viral causes of hepatitis, and auto-immune antibodies. Biliary obstruction was excluded by appropriate imaging studies. Liver biopsy was obtained, though not definitive.

Results

After detailed investigation failed to reveal a cause of the jaundice, an empiric trial of steroids was initiated on the possibility that our patient had antibody-negative AIH and not DILI, with an associated grave prognosis.

Conclusions

Empiric treatment with prednisone led to rapid resolution of jaundice and to the conclusion that the correct diagnosis was antibody-negative AIH.
Literature
1.
go back to reference Zimmerman HJ. Drug-induced liver disease. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 1st ed. New York: Appleton-Century-Crofts; 1978:351–353. Zimmerman HJ. Drug-induced liver disease. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 1st ed. New York: Appleton-Century-Crofts; 1978:351–353.
2.
go back to reference Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, et al. Acute hepatitis e infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665–1672.PubMedCentralPubMedCrossRef Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, et al. Acute hepatitis e infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665–1672.PubMedCentralPubMedCrossRef
3.
go back to reference Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479–497.PubMedCrossRef Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479–497.PubMedCrossRef
6.
go back to reference Donaghy L, Fergus JB, Hunter JG, Stableforth W, et al. Clinical and laboratory features and natural history of seronegative hepatitis in a nontransplant centre. Eur J Gastroenterol Hepatol. 2013;25:1159–1164.PubMed Donaghy L, Fergus JB, Hunter JG, Stableforth W, et al. Clinical and laboratory features and natural history of seronegative hepatitis in a nontransplant centre. Eur J Gastroenterol Hepatol. 2013;25:1159–1164.PubMed
Metadata
Title
A Case of Jaundice of Obscure Origin
Authors
Fahad M. Khan
Joseph Alcorn
Joshua Hanson
Publication date
01-05-2014
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2014
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3114-6

Other articles of this Issue 5/2014

Digestive Diseases and Sciences 5/2014 Go to the issue

Stanford Multidisciplinary Seminars

Two Evils: Gastrocolic Fistula and Heart Failure

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine